Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2014
At a glance
- Drugs Gemcitabine (Primary) ; Lenalidomide (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms LENAGEM-PANC
- 26 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Jun 2012 Company added in the association field as reported by EudraCT.
- 02 Mar 2012 Additional lead trial centres, lead trial investigators and Celgene Corporation as company identified as reported by ClinicalTrials.gov.